Ann: Cough analysis patent granted in China, page-82

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 82 Last

Share
Profile

Follow
FredP

620 Posts.

93

02/02/22

16:59

Post #: 59307504
Share

Originally posted by hilzi: ↑

I have been following the RAP saga for 2 years now and have been an enthusiastic, very nervous, highly concerned / frustrated and as of late very pleased shareholder. It really looks like we are starting to turn corners.

Right now, I see a very positive trajectory for the company and agree with the excitement posted by others. Two concerns currently make me a bit hesitant to invest more in RAP, which is already quite overweight in my humble portfolio - would be interested in others' opinions:

(1) $124k Q2 revenue is great, but what if the majority is an advance payment from J&J and the whole Telehealth pipeline is growing at a much lower rate as many are thinking here?
(2) Covid screening sounds like a real opportunity, fingers crossed on the data. But if that is positive, how would a globally scalable platform be developed to process all those potential tests? This is way beyond RAP's means, so in best case would require a JV partner. In worst (but still good) case RAP might become a takeover candidate at a SP quite far south of some of the poster's dreams...

As I said, I don't want to sound negative, when I feel more positive about this investment than I ever have. But would like to get more thoughts on those areas of potential concern...

Expand

Re: point two - wouldn't it be on the Iphone/phone that your results come up - it wouldn't need processing - it would be instant I would assume. Like a RAT test gives you the line - you don't need to process or submit that.

RAP Price at posting: 7.5¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

First 82 Last

Add RAP (ASX) to my watchlist

Ann: Cough analysis patent granted in China, page-82

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Featured News